Multi-modal contrast agent based on polyamino acid nano-micelle as well as preparation method and application of multi-modal contrast agent

By combining fluorescent dyes, CT and magnetic resonance contrast agents based on polyamino acid nanomiles, the problem of incoordination of imaging modes in the prior art is solved, and CT/magnetic resonance/fluorescence synchronous imaging is achieved. Improves diagnostic efficiency and accuracy.

CN118987283APending Publication Date: 2024-11-22HANGZHOU ULTRA-THERANOSTICS BIOPHARMACEUTICALS TECHNOLOGY CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411498379.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-25
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

In the existing multimodal imaging technology, a single imaging mode has shortcomings in spatial resolution, soft tissue resolution, tissue penetration, sensitivity and accuracy, making it difficult to provide comprehensive and comprehensive information for cancer diagnosis and monitoring, and now There are contrast agents that have different circulation times and distributions in the body, making it difficult to achieve synchronous imaging.

Method used

Using a multimodal contrast agent based on polyamino acid nanomiles, combined with fluorescent dye, CT contrast agent and magnetic resonance contrast agent, it is prepared by covalent coupling and solvent replacement method to form a nanomilk carrier to achieve CT/magnetic resonance/ Coordinated and unified distribution of fluorescent multimodal contrast agents.

Benefits of technology

CT/magnetic resonance/fluorescence synchronous imaging is realized, the operation process is simplified, the imaging efficiency is improved, the precise positioning and diagnosis of lesions is ensured, and the gap in the existing technology that cannot achieve simultaneous imaging of magnetic resonance, CT and fluorescence scanning are not possible. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987283A_ABST
    Figure CN118987283A_ABST
Patent Text Reader

Abstract

The invention provides a multi-modal contrast agent based on polyamino acid nano-micelles as well as a preparation method and application thereof, and belongs to the technical field of medical contrast agents. According to the multi-mode contrast agent, fluorescent dye and polyamino acid are combined through covalent bonds to obtain fluorescent dye labeled polyamino acid, and trivalent bismuth ions and trivalent iron ions are chelated through a catechol structure of a polydopa block side chain to obtain the CT / magnetic resonance / fluorescent multi-mode contrast agent. The multi-modal contrast agent is simple and convenient to prepare, good in biocompatibility and excellent in imaging effect. By using the multi-modal contrast agent disclosed by the invention, the tedious operation of injecting multiple contrast agents at the same time can be avoided, so that the pain of a patient is effectively relieved. The multi-modal contrast agent provided by the invention does not interfere with each other in the imaging process of each modal, and can synchronously image and fully exert the effect of advantage complementation, so that accurate image diagnosis of a focus is realized to better adapt to clinical requirements.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of medical contrast agents, and specifically relates to a multimodal contrast agent based on polyamino acid nano-micelles, a preparation method and an application thereof; more specifically, it relates to a preparation method of a CT / magnetic resonance / fluorescence multimodal contrast agent based on polymer nano-micelles and an application thereof. Background Art

[0002] The cure rate of early cancer patients is high, so early diagnosis of cancer is crucial to reducing the mortality rate of cancer patients. Diagnostic imaging technologies for cancer include: magnetic resonance (MR) imaging, X-ray computed tomography (CT) imaging, and fluorescence (FL) imaging. However, a single imaging mode has deficiencies in spatial resolution, soft tissue resolution, tissue penetration, sensitivity and accuracy, and it is difficult to provide comprehensive information for cancer diagnosis and monitoring. The combination of multiple imaging modes can greatly make up for the above shortcomings, and by combining the advantages of each single-modality imaging technology, it can comprehensively reflect the occurrence and development of cancer.

[0003] In existing technologies, multimodal imaging requires the simultaneous injection of multiple contrast agents, which is cumbersome to operate and difficult to achieve synchronous imaging due to the different circulation times and distributions of various contrast agents in the body. Currently, there are many studies on integrating multiple contrast agents into the same carrier to prepare multimodal contrast agents.

[0004] Jin et al. studied a novel polyethylene glycol dysprosium (Dy)-doped NaGdF4 nanoprobe (PEG-NaGdF4:Dy) as an imaging agent, however, due to the use of gadolinium, there is a risk of brain deposition in imaging applications.

[0005] Li et al. disclosed a urokinase-type plasminogen activator receptor (uPAR)-targeted dendritic poly-lysine (DGL)-U11 magnetic resonance (MR) / near-infrared fluorescence (NIRF) dual-modality nanoprobe for ultra-early detection of pancreatic precancerous lesions. This probe also used gadolinium, which leads to the risk of brain deposition.

[0006] Due to the complex synthesis and difficult preparation of multimodal contrast agents and the unclear mechanism of mutual influence between contrast agents of each modality, there is currently no mature contrast agent material that can effectively combine the three imaging methods of magnetic resonance imaging, X-ray computed tomography imaging and fluorescence imaging. Existing contrast agents cannot achieve simultaneous imaging of magnetic resonance, X-ray computed tomography and fluorescence scanning. If the existing conventional CT contrast agent, MR contrast agent and fluorescence contrast agent are mixed and injected, the three contrast agents cannot be uniformly distributed in the body, which makes it difficult to achieve multimodal imaging of the same lesion.

[0007] Therefore, it is necessary to construct a new contrast agent that can achieve the synergistic unification of magnetic resonance imaging, CT, and fluorescence imaging, so that each imaging mode can make up for its own shortcomings while playing its respective advantages, improve imaging efficiency, and achieve multimodal imaging of the same lesion. Summary of the invention

[0008] In view of the problems existing in the prior art, the present invention provides a multimodal contrast agent based on polyamino acid nano-micelles, a preparation method and an application thereof, so as to make up for the shortcomings of single-mode imaging contrast agents, such as incomplete and inaccurate imaging, and achieve accurate positioning and diagnosis of lesions.

[0009] Firstly, the present invention provides a multimodal contrast agent based on polyamino acid nano-micelles, comprising components: a fluorescent dye, a CT contrast agent, a magnetic resonance contrast agent and a nano-micelle carrier; The fluorescent dye is selected from at least one of cyanine (CY) dyes, boron dipyrrole fluoride (BODIPY) dyes, heptamethine cyanine series dyes, fluorescein isothiocyanate (FITC isothiocyanate), and indocyanine green NHS ester (ICG NHS ester) dyes; The CT contrast agent contains Bi 3+ of substances; The magnetic resonance contrast agent is Fe 3+ of substances; The nanomicelle carrier is an amphiphilic polymer, one segment of which contains at least one polydopa block (PDOPA) and the other segment is a hydrophilic polymer block.

[0010] Preferably, among the fluorescent dyes, the types of cyanine dyes are not limited to CY3 NHS ester, CY5 NHS ester, and CY7NHS ester; the types of boron dipyrrole fluoride dyes are not limited to BDP 558 / 568 NHS ester, BDP 581 / 591 NHSester, and BDP R6G NHS ester; the types of heptamethine cyanine series dyes are not limited to IR780 NHS ester, IR808 NHSester, and IR820 NHS ester.

[0011] Further preferably, the fluorescent dye is selected from at least one of fluorescein isothiocyanate and indocyanine green NHS ester.

[0012] Preferably, the nanomicelle carrier is an amphiphilic polydopa-polysarcosine (PDOPA- b -PSar).

[0013] More preferably, in the amphiphilic polydopa-polysarcosine, the chain length of polydopa amino acid is 1-200, and the chain length of polysarcosine is 1-2000.

[0014] More preferably, the polydopa amino acid has a chain length of 20-50, and the polysarcosine has a chain length of 50-200.

[0015] Further preferably, the nanomicelle carrier is PDOPA 37 - b -PSar 118 .

[0016] Preferably, the hydrophilic polymer block in the nano-micelle carrier is selected from at least one of polysarcosine, polyethylene glycol, polyvinyl alcohol and polyacrylic acid.

[0017] Further preferably, the hydrophilic polymer block in the nanomicelle carrier is polysarcosine.

[0018] Preferably, in the multimodal contrast agent, the nanomicelle carrier is covalently coupled to a fluorescent dye to obtain a fluorescent dye-labeled nanomicelle carrier (fluorescent dye-labeled amphiphilic polymer); the structural formula of the fluorescent dye-labeled nanomicelle carrier is: ; R1 is selected from one of an alkyl group, a benzyl group, and a silicon group; R2 is a fluorescent dye; m=1-200, n=1-2000.

[0019] More preferably, m=20-50, n=50-200.

[0020] Preferably, the CT contrast agent is Bi 3+ Chelate, its chemical structure is: .

[0021] Preferably, the magnetic resonance contrast agent is Fe 3+ Chelate, its chemical structure is: .

[0022] Preferably, the molar ratio of the chain terminal amine group of the nanomicelle carrier to the fluorescent dye is 0.5-10:1; further preferably, the molar ratio of the chain terminal amine group of the nanomicelle carrier to the fluorescent dye is 2-4:1.

[0023] Preferably, in the multimodal contrast agent, phenolic hydroxyl group: Bi 3+ +Fe 3+ The molar ratio is 0.5-6:1.

[0024] Further preferably, in the multimodal contrast agent, phenolic hydroxyl group: Bi 3+ +Fe 3+The molar ratio is 1-3:1.

[0025] More preferably, in the multimodal contrast agent, phenolic hydroxyl group: Bi 3+ +Fe 3+ The molar ratio is 1-1.4:1.

[0026] Further preferably, the Bi 3+ and Fe 3+ The molar ratio is 1-2:1.

[0027] Further preferably, the Bi 3+ and Fe 3+ The molar ratio is 1:1.

[0028] Preferably, the particle size of the multimodal contrast agent is 10-500 nm.

[0029] Further preferably, the particle size of the multimodal contrast agent is 10-100 nm.

[0030] Furthermore, the present invention provides a method for preparing the above-mentioned multimodal contrast agent, comprising the steps of: connecting a fluorescent dye to the end of a nanomicelle carrier by covalent coupling, complexing a polyamino acid labeled with a fluorescent dye with a CT contrast agent and a magnetic resonance contrast agent, and obtaining a multimodal contrast agent by a solvent replacement method.

[0031] Preferably, the preparation method of the multimodal contrast agent comprises the steps of: connecting a fluorescent dye to the end of a polydopa-polysarcosine block copolymer chain in a covalent coupling manner, and coupling a polyamino acid labeled with a fluorescent dye to a trivalent bismuth ion (Bi 3+ ) and ferric iron (Fe 3+ ) compounds and obtained a multimodal contrast agent by solvent replacement method.

[0032] Preferably, the molar ratio of the chain terminal amine group of the nanomicelle carrier to the fluorescent dye is 0.5-10:1; further preferably, the molar ratio of the chain terminal amine group of the nanomicelle carrier to the fluorescent dye is 2-4:1.

[0033] Preferably, in the multimodal contrast agent, phenolic hydroxyl group: Bi 3+ +Fe 3+ The molar ratio is 0.5-6:1.

[0034] Further preferably, in the multimodal contrast agent, phenolic hydroxyl group: Bi 3+ +Fe 3+ The molar ratio is 1-3:1.

[0035] More preferably, in the multimodal contrast agent, the phenolic hydroxyl group and: Bi 3+ +Fe3+ The molar ratio is 1-1.4:1.

[0036] Further preferably, the Bi 3+ and Fe 3+ The molar ratio is 1-2:1.

[0037] More preferably, the Bi 3+ and Fe 3+ The molar ratio is 1:1.

[0038] The fluorescent dye of the present invention refers to a chemical substance that absorbs light energy of a specific wavelength and re-emits light at a different wavelength; the fluorescent dye of the present invention can be covalently coupled to the primary amine or secondary amine group on the polyamino acid to form a stable chemical connection.

[0039] Finally, the present invention provides the use of nano micelle carriers containing trivalent bismuth ions, trivalent iron ions and fluorescent dyes in the preparation of multimodal contrast agents.

[0040] Compared with the prior art, the present invention has the following beneficial effects: (1) The multimodal contrast agent provided by the present invention is easy to prepare, has good biocompatibility, and has excellent imaging effect.

[0041] (2) The multimodal contrast agent provided by the present invention can avoid the tedious operation of injecting multiple contrast agents at the same time, thereby effectively alleviating the patient's pain.

[0042] (3) The multimodal contrast agent provided by the present invention does not interfere with each other during the imaging process of each modality, and can realize CT / magnetic resonance / fluorescence simultaneous imaging, thereby achieving the purpose of accurate positioning and diagnosis of lesions, filling the gap in multimodal contrast agents that can simultaneously realize three types of imaging. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1 This is the dynamic light scattering diagram of the multimodal contrast agent in Example 1.

[0044] Figure 2 This is the in vitro CT imaging of the multimodal contrast agent in Example 1 and its intensity-concentration relationship diagram.

[0045] Figure 3 Graph showing the relationship between the in vitro longitudinal relaxation time (T1) and the iron ion concentration of the multimodal contrast agent in Example 1.

[0046] Figure 4 : is the fluorescence spectrum of the multimodal contrast agent in Example 1. DETAILED DESCRIPTION

[0047] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is merely an exemplary description of the scope of the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, which should also fall within the scope of the present invention.

[0048] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meanings as those generally understood by those of ordinary skill in the art to which the present invention belongs.

[0049] The present invention is further described below by way of specific examples. Unless otherwise specified, the various chemical reagents used in the examples of the present invention are obtained through conventional commercial channels.

[0050] DLS (dynamic light scattering) test method: The hydrodynamic diameter of the multimodal contrast agent based on polyamino acid nanomicelles in aqueous solution was detected by a Zetasizer Nano Series (Malvern Instruments) detector with a measurement wavelength of 657 nm and a fixed angle of 90°. Each sample was tested three times in parallel.

[0051] In vitro CT imaging test method: In vitro CT images and their intensity-concentration relationship diagrams were measured by a Siemens dual-source CT scanner (SOMATOM Definition Flash, Siemens, Germany) with a tube voltage of 120 kV.

[0052] Method for detecting the relationship between in vitro longitudinal relaxation time and iron ion concentration: The T1-weighted magnetic resonance imaging r1 relaxation rate of the metal chelated polyamino acid nanoparticle solution was measured in a 3.0T magnetic resonance imaging instrument (Signa HDxt, GE Medical Systems, Milwaukee, WI, USA).

[0053] Fluorescence spectrum detection method: Fluorescence excitation and emission spectra were tested on FLS1000 fluorescence spectrometer (Edinburghinstrument).

[0054] Example 1 Preparation of CT / MRI / fluorescence multimodal contrast agents: First weigh 123 mg PDOPA 37 - b -PSar 118(nano-micelle carrier, R1 is neopentylamine) and 1.2mg FITC isothiocyanate (fluorescent dye, R2), and dissolved them in 2.5mL DMSO (nano-micelle carrier chain terminal amine group: FITC isothiocyanate = 2:1, molar ratio), stirred overnight in the dark. Then slowly add DMSO (8mL) solution containing 147mg Bi(NO3)3·5H2O and 122mg Fe(NO3)3·9H2O (phenolic hydroxyl group: Bi 3+ :Fe 3+ =2:1:1, molar ratio), dialyzed in deionized water for 96 h. The obtained micellar solution was filtered through a 0.45 µm filter membrane and fixed to volume for later use.

[0055] The structural formula of the fluorescent dye-labeled nanomicelle carrier of this embodiment is: .

[0056] After testing, the encapsulation efficiency of bismuth ions and iron ions were 63.5% and 35.3%, respectively.

[0057] The DLS test results of micelles are as follows Figure 1 As shown, the average particle size of the obtained multimodal contrast agent micelles is 35 nm.

[0058] In vitro CT imaging and results Figure 2 As shown, the CT intensity of the multimodal contrast agent micelles is positively linearly correlated with the bismuth ion concentration, and its CT contrast efficiency is 58.0.

[0059] The in vitro experimental results on the relationship between the longitudinal relaxation time (T1) of multimodal contrast agents and iron ion concentration are as follows Figure 3 As shown, the longitudinal relaxivity of the multimodal contrast agent is 1.507 mM -1 s -1 .

[0060] In vitro fluorescence analysis showed that the multimodal contrast agent had obvious fluorescence excitation and emission at 493nm and 519nm, respectively. Figure 4 ).

[0061] from Figure 2-Figure 4 It can be seen that the multimodal contrast agent of the present invention can realize simultaneous magnetic resonance (MR) imaging, X-ray computed tomography (CT) imaging and fluorescence (FL) imaging in detection, and achieves good imaging effect.

[0062] Example 2 The difference from Example 1 is that FITC isothiocyanate is replaced by indocyanine green NHS ester (ICG NHS ester) (nanomicelle carrier chain terminal amine group: indocyanine green NHS ester = 4:1, molar ratio), phenolic hydroxyl group: Bi 3+:Fe 3+ The molar ratio is 4:2:1.

[0063] The structural formula of the fluorescent dye-labeled nanomicelle carrier of this embodiment is: .

[0064] After testing, the encapsulation efficiency of bismuth ions and iron ions were 67.1% and 21.3%, respectively.

[0065] The average particle size of the multimodal contrast agent prepared in this example is 15 nm, and the longitudinal relaxation rate is 1.068 mM -1 s -1 , a CT contrast efficiency of 47.8, and fluorescence excitation and emission at 789 nm and 810 nm.

[0066] Example 3 The difference from Example 1 is that 1.2 mg FITC isothiocyanate is replaced by 0.24 mg FITC isothiocyanate, that is, the molar ratio of the terminal amine group of the nanomicelle carrier chain to FITC isothiocyanate is 10:1.

[0067] After testing, the encapsulation efficiency of bismuth ions and iron ions were 65.7% and 32.5%, respectively.

[0068] The average particle size of the multimodal contrast agent prepared in this example is 30 nm, and the longitudinal relaxation rate is 1.478 mM -1 s -1 , a CT contrast efficiency of 51.2, and fluorescence excitation and emission at 493 nm and 519 nm.

[0069] Example 4 The difference from Example 1 is that the phenolic hydroxyl group: Bi 3+ :Fe 3+ The molar ratio is 12:1:1.

[0070] After testing, the encapsulation efficiency of bismuth ions and iron ions were 88.1% and 45.2%, respectively.

[0071] The average particle size of the multimodal contrast agent prepared in this example is 25 nm, and the longitudinal relaxation rate is 1.022 mM -1 s -1 , a CT contrast efficiency of 30.3, and fluorescence excitation and emission at 493 nm and 519 nm.

[0072] Comparative Example 1 The commercially available MRI contrast agent glucagon-deoxyglucose injection (Gd-DTPA) was purchased from Beijing Beilu Pharmaceutical Co., Ltd.

[0073] After testing, it was found that the contrast agent does not have the effects of CT imaging and simultaneous fluorescence imaging, and cannot achieve simultaneous imaging of magnetic resonance imaging, CT and fluorescence.

[0074] Comparative Example 2 The commercially available CT contrast agent iohexol was purchased from Omnipaque.

[0075] After testing, it was found that the contrast agent does not have the effects of CT imaging and simultaneous fluorescence imaging, and cannot achieve simultaneous imaging of magnetic resonance imaging, CT and fluorescence.

[0076] Comparative Example 3 The commercially available magnetic resonance contrast agent glucagon disodium tartrate injection (Gd-DTPA), the CT contrast agent iohexol and the fluorescent dye fluorescein isothiocyanate are mixed in a molar ratio of 1:1:1 to obtain a contrast agent mixture.

[0077] The contrast agent mixture cannot achieve real-time imaging of the same lesion in vivo via magnetic resonance imaging, CT, and fluorescence detection.

[0078] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. A multimodal contrast agent based on polyamino acid nanomicelles, characterized in that: The components include: fluorescent dye, CT contrast agent, magnetic resonance contrast agent and nano micelle carrier; The fluorescent dye is selected from at least one of cyanine dyes, boron dipyrrole fluoride dyes, heptamethine cyanine dyes, fluorescein isothiocyanate, and indocyanine green NHS ester dyes; The CT contrast agent contains Bi 3+ of substances; The magnetic resonance contrast agent is Fe 3+ of substances; The nano-micelle carrier is an amphiphilic polymer, one segment of which contains at least one polydopa block, and the other segment is a hydrophilic polymer block.

2. The multimodal contrast agent according to claim 1, characterized in that: Among the fluorescent dyes, the types of cyanine dyes are not limited to CY3 NHS ester, CY5 NHS ester, and CY7 NHS ester; the types of boron dipyrrole fluoride dyes are not limited to BDP558 / 568 NHS ester, BDP 581 / 591 NHS ester, and BDP R6G NHS ester; the types of heptamethine cyanine series dyes are not limited to IR780 NHS ester, IR808 NHS ester, and IR820 NHS ester.

3. The multimodal contrast agent according to claim 1, characterized in that: The nano micelle carrier is amphiphilic polydopa-polysarcosine; the length of the chain link of polydopa amino acid is 1-200, and the length of the chain link of polysarcosine is 1-2000.

4. The multimodal contrast agent according to claim 3, characterized in that: The chain length of the polydopa amino acid is 20-50, and the chain length of the polysarcosine is 50-200.

5. The multimodal contrast agent according to claim 1, characterized in that: The hydrophilic polymer block in the nano-micelle carrier is selected from at least one of polysarcosine, polyethylene glycol, polyvinyl alcohol and polyacrylic acid.

6. The multimodal contrast agent according to claim 1, characterized in that: The nanomicelle carrier is connected to the fluorescent dye by covalent coupling to obtain a nanomicelle carrier labeled with the fluorescent dye; the structural formula of the nanomicelle carrier labeled with the fluorescent dye is: ; R1 is selected from one of an alkyl group, a benzyl group, and a silicon group; R2 is a fluorescent dye; m=1-200, n=1-2000.

7. The multimodal contrast agent according to claim 1, characterized in that: The CT contrast agent is Bi 3+ Chelate, its chemical structure is: ; The magnetic resonance contrast agent is Fe 3+ Chelate, its chemical structure is: 。 8. The multimodal contrast agent according to claim 1, characterized in that: The molar ratio of the chain terminal amine group of the nanomicelle carrier to the fluorescent dye is 0.5-10:1; Phenolic hydroxyl:Bi 3+ +Fe 3+ The molar ratio is 0.5-6:1; The Bi 3+ and Fe 3+ The molar ratio is 1-2:1; The particle size of the multimodal contrast agent is 10-500 nm.

9. The method for preparing the multimodal contrast agent according to any one of claims 1 to 8, characterized in that: The method comprises the following steps: connecting the fluorescent dye to the end of the nano-micelle carrier in a covalent coupling manner, complexing the polyamino acid labeled with the fluorescent dye with the CT contrast agent and the magnetic resonance contrast agent, and obtaining the multimodal contrast agent by a solvent replacement method.

10. Use of a nano-micelle carrier in the preparation of a multimodal contrast agent, characterized in that: The nano-micelle carrier is a nano-micelle carrier in the multimodal contrast agent according to any one of claims 1 to 8; specifically, it is a nano-micelle carrier containing trivalent bismuth ions, trivalent iron ions and fluorescent dyes.

Citation Information

Patent Citations

  • Amphiphilic polymer nano micelle containing ferric ions chelated with polydopa amino acid and application thereof

    CN110496231A

  • X-ray shielding coating, preparation method and medical material containing X-ray shielding coating

    CN117071294A